Astract. The hypoproliferative anemia in chronic renal failure has been assumed to be the result of decreased erythropoietin (Ep) production by the damaged kidney and ofthe shortening oferythrocyte survival. However, many in vitro studies suggest that erythropoietic inhibitors in uremic plasma may contribute to the anemia. To determine the in vivo relevance of uremic inhibitors, increasing amounts of Ep as Ep-rich plasma were infused into six uremic sheep, and their erythropoietic responses were compared with those of nine normal sheep receiving similar amounts of Ep-rich plasma. Three sheep were studied in both normal and uremic states. Ep-rich plasma was obtained from phenylhydrazine-and phlebotomyinduced anemic sheep. Stable uremia was created by subtotal nephrectomy. Erythropoiesis was quantitated by reticulocyte response, ferrokinetics (plasma iron turnover and marrow transit time), and by hemoglobin C synthesis. Ep-rich plasma stimulated erythropoiesis similarly in uremic and normal sheep, regardless of the degree of uremia. Nondialyzed uremic sheep responded as well as dialyzed animals. The anemia was corrected in the uremic sheep after 15-40 daily infusions of Ep-rich plasma, the total dosage depending on the severity of the anemia. Polycythemia was induced when the infusions were continued. Reticulocytes, plasma iron turnover, and erythrocyte mass changes increased as the amount of Ep-rich plasma was increased. These dose-response effects, coupled with the identical erythropoietic response in normal
Introduction
Erythropoietin (Ep)' production is a primary function of the kidney (1), and Ep is secreted in response to complex interactions involved with oxygen delivery. The anatomical site and the cellular or subcellular mechanisms by which the kidney recognizes altered oxygen availability are unknown. But the response to anemia in normal animals and humans is an orderly sequence of increased Ep production followed by increased marrow erythropoiesis and an increase in the effective delivery of new erythrocytes to the circulation. Ep also increases cellular hemoglobin (Hb) synthesis and stimulates the terminal differentiation of committed erythroid progenitors (2) . An additional effect, seen in goats and certain sheep, is the switch in the synthesis of the usual adult hemoglobin beta chain, flA, to the synthesis of a structurally distinct beta chain, fl3 (3). Thus, sheep of phenotype HbAA (a2l32A) will change phenotype to HbCC (a2l32C) with erythropoietic stress. Sheep with the other common beta chain (#B) do not undergo such a change.
Because of the kidney's central role in erythrocyte production, anemia is a major complication of chronic renal failure (CRF). Of the -70,000 patients on maintenance dialysis in the United States, more than 98% are anemic (4) and more than 60% require periodic erythrocyte transfusions (5) . Despite transfusions, anemia persists and remains a major factor in preventing better rehabilitation of chronically uremic patients.
There are two definite mechanisms that contribute to the anemia of renal failure: a decreased Ep production by the diseased kidney, resulting in marrow hypoproliferation (6) , and a shortening of erythrocyte survival (7) . A third possible mech-anism, the depression of bone marrow proliferation by ill defined inhibitors (8) , has been suggested by both in vitro and in vivo studies, but the interpretations of the data are controversial. Although many in vitro studies note the presence of inhibitors to erythropoiesis in uremia, the clinical significance of these inhibitors has been difficult to define. Inhibitors oferythropoiesis, if present in CRF, could significantly alter the response to Ep. Therefore, the most critical test of the relevance of uremic inhibitors defined in vitro would be determined by the results of Ep infusions in vivo.
Since not enough purified human Ep is available to study its effects in vivo, we prepared endotoxin-free Ep-rich plasma from sheep made severely anemic by phenylhydrazine and repeated phlebotomy. The use of homologous Ep in a large sheep model of CRF (9) [10] ), and the creation of a vascular access before studies in the normal state. A silastic catheter with a Dacron cuff was inserted through the jugular vein and its tip was placed in the right atrium (11) . Catheter sterility was maintained by instilling 1 ml of a solution of 0.5% formalin in acid citrate dextrose into the catheter three times a week. 15 min after being instilled, this solution was aspirated and replaced with 1 ml of a heparin solution (1,000 U/ml) to ensure catheter patency (12) . The surgical two-stage procedure for creating CRF has been described previously (9 (14) and radioimmunoassay (RIA) (15) , disclosed similar concentrations, ranging from 0.4 to 2.1 U/ml. All pools were free of endotoxin (16) .
Study protocol. Three Ep infusion protocols were employed: (a) Ep was given at a dosage of 10-27 U/kg; this was administered in two doses 24 h apart, and infused as 500 ml of Ep-rich plasma over 20-30 min. (b) Twice the original dosage was given 3 wk later, again in two doses, 24 h apart. (c) 3 wk later, one-half of the original dose was given daily for 10 d. The same pool of Ep-rich plasma was used for all studies in a given animal. 500 ml of plasma from donor sheep with a normal hematocrit were infused on two separate days and served as a control for the Ep infusions. Protocols 1-3 were carried out in normal animals, but protocol 2 was omitted for uremic sheep in order to conserve Ep.
After the above studies were completed in the anemic, uremic sheep, the infusions were continued daily until the hematocrit returned to normal. In three such sheep, infusions were continued until polycythemia (hematocrit 2 40) occurred.
Laboratory evaluation. The erythropoietic response to Ep-rich plasma infusions was quantitated by reticulocyte count, plasma iron turnover (PIT) (17) , marrow transit time (MTT) (17) , and the extent of HbC synthesis in HbAA or AB animals (18 in the collected fractions was determined with a gamma counter and the hemoglobins were analyzed. Radioactivity in each fraction for hemoglobins A, B, and C (marked by carrier hemoglobins) was then expressed as a percentage ofthe total counts obtained. Radioactivity already present in the peripheral blood (as a result of prior ferrokinetic studies) was considered insignificant if it was <5% of the total 59Fe uptake by the marrow cells. In a few samples, the amount of radioactivity present in peripheral blood was significant. This was corrected by analyzing HbC from marrow cells both before and after in vitro incubation with 59Fe. The percentage HbC synthesis was then calculated by subtracting the radioactivity present in the original sample from the 59Fe uptake by the marrow cells in vitro. Ep was measured both by the standard exhypoxic polycythemic mouse bioassay (14) and by RIA (15) . The RIA-Ep levels were quantitated by comparison with a simultaneously assayed sheep standard Ep of known activity.
Plasma was analyzed for creatinine, urea nitrogen, potassium, sodium, bicarbonate, chloride, glucose, phosphorus, and calcium with an autoanalyzer.
Statistical analysis. The two-sample t test for unequal variances (21) was used to test for differences between the mean parameter values of normal and uremic sheep in Tables I and II To determine the statistical significance of these relationships, the slope coefficients were tested by the ratio ofeach slope coefficient to its standard error, which has a t distribution. In Figs. 4 and 5, the separate regression lines for normal sheep and uremic sheep were tested for coincidence (equal slopes and equal intercepts) with the dummy variable multiple regression model (22) . The significance of the results is expressed as a probability value. Significance is considered .0.05.
Results
Nine normal sheep were studied; eight completed all studies and one received only one dose of Ep-rich plasma.
Six sheep were studied when uremic. Three had been studied when normal and three were made uremic without having been studied. One uremic sheep was studied twice and the averages of the observations from each study were used in the analyses. The dialyzed sheep survived for 6, 7, and 8 mo; the nondialyzed uremic sheep survived for 9, 1 1, and 21 mo. Technical complications of dialysis (water-induced hemolysis) and intractable pulmonary edema accounted for the shorter survival of the dialyzed sheep. The RIA Ep levels in normal animals ranged from 20.6 to 56.6 mU/ml (mean 36.4±6.7) at a hematocrit of 32.3±2.1. The RIA Ep levels in uremic, anemic sheep ranged from 12.6 to 103 mU/ml (mean 45.9±14.4), hematocrit 19.2±2.2). As seen in Fig. 1 , the uremic sheep had lower Ep levels than normal animals made equally anemic by phenylhydrazine and/or phlebotomy. Table II details the erythropoietic responses to infusions of normal plasma and various dosages of Ep-rich plasma. Normal plasma infusions had no effect on the four parameters of erythropoiesis in either study state. Not all studies were performed in all animals; some sheep were of HbBB phenotype and in others, marrow could not be aspirated, preventing the measurement ofHbC synthesis. There were no statistically significant differences between any ofthe erythropoietic reponse parameters for normal or uremic animals studied during the baseline period, Fig. 2 compares the effect of the same amount of Ep-rich plasma given to a sheep when normal and later, when uremic. The increases in reticulocyte count and PIT were essentially identical regardless of the degree of renal function. Two other animals had similar responses to the same amount of Ep-rich plasma in both study states (data not shown). Table III shows the results of studies in five anemic, uremic sheep given daily infusions of Ep-rich plasma to normalize their hematocrits. The hematocrit was normalized twice in one animal; after the Ep-rich plasma infusions were discontinued, 2 mo elapsed before the hematocrit spontaneously returned to a stable anemic level. When the increase in erythrocyte mass was compared with the total amount of Ep given, a significant correlation was obtained (Fig. 3) . Similar results were observed when the response of normal and uremic sheep to infused Ep-11 P value estimated by rich plasma was analyzed by correlating Ep dose to the peak change in reticulocyte count or PIT (Figs. 4 and 5 ). There were significant linear relationships between log Ep dose and reticulocyte count in normal and uremic sheep (P < 0.002 and 0.05, respectively) and between log Ep dose and PIT (P = 0.01 and 0.05, respectively). However, there were no significant differences in either the slopes or intercepts ofthe regression lines (coincident lines) between the two groups, which indicates that the amount of response of the reticulocyte count and PIT per unit change in log dose of Ep was the same in normal and uremic sheep.
Three animals continued to receive Ep-rich plasma, which eventually induced polycythemia. Fig. 6 (27) , Ep levels have usually been undetectable in anemic, uremic patients (28, 29) , although subnormal levels are difficult to quantitate by this method. An improved bioassay which uses concentrations of plasma (30) disclosed that normal subjects had levels ranging from 3.9 to 15.4 mU/ml, whereas halfofthe nephric, uremic patients studied had similar levels and the other halfhad elevated levels. Although no correlative studies of total and effective erythropoiesis were performed, the finding of elevated Ep levels in a substantial Consistent with this was the finding of markedly elevated Ep levels in a very anemic anephric dialysis patient (31) . Since the purification of Ep (32) , which led to the subsequent development of an RIA for Ep (15, 33) , levels in normal and uremic subjects can be measured more easily (34) . The serum levels of Ep in normal males and females were reported to be 17-19 mU/ml as measured by RIA (34), whereas the mean serum level was 28±6 mU/ml in anemic, uremic dialyzed patients (35) and~-20 mU/ml (15), similar to normal, in anephric patients. The serum Ep levels in the normal and uremic sheep (Table I) were similar to values observed in normal and uremic humans. We interpret these findings to indicate that maximal Ep secretion, in response to anemia, is reduced because of the decreased functional renal mass in CRF. However, it is also conceivable that biologically inactive fragments of Ep retained in CRF could result in apparently normal or even elevated levels of Ep measured by RIA (33) .
Studies in animals have also failed to clarify the roles of Ep deficiency and uremic inhibition in the anemia of CRF. Peritoneally dialyzed anephric rats responded to very large amounts of sheep Ep in one study (36) but not in another (37). Rats, uremic from subtotal nephrectomy, responded to rat Ep (38, 39), but stable uremia was not achieved with this model. Mice with hereditary polycystic kidney disease responded to human urinary Ep if they were mildly azotemic but failed to respond when more uremic (23).
Studies in man on the effectiveness of Ep in the anemia of Ep, and BPA has not been demonstrated to be relevant in vivo. Nevertheless, until purified Ep is available, we cannot conclude unequivocally that it was only Ep that produced the erythropoietic changes noted in our uremic sheep. Since purified sheep Ep from which to make an antibody is unavailable, Ep could not be completely removed from the anemic plasma to serve as a control. Nevertheless, even if stimulating factors in addition to Ep were present in the anemic plasma, they were infused equally into both normal and uremic sheep, and no inhibition of Ep or of any other stimulating factor was observed.
The possibility that erythropoietic inhibitors could be present but masked by excessive amounts ofthe infused hormone seems unlikely. This is supported by the finding that increasing amounts of plasma resulted in a progressively greater response, as quantitated by ferrokinetics, reticulocytosis, and erythrocyte mass. If inhibitors were present and larger amounts of Ep overcame the inhibition, a linear in vivo dose-response curve would not be predicted.
These animal studies suggest that Ep therapy should correct the hypoproliferative anemia of CRF. The amount required should be less than previously predicted, since uremic inhibition may not be present. In addition, Ep will be required only intermittently since the hematocrit may not return to anemic levels for several months after hormone infusions are stopped. The uremic sheep requires less than 10 U of Ep/kg for 15-40 d (depending on the severity ofthe anemia) to correct the anemia. It is likely that a smaller, but as yet unknown, quantity of Ep would be required for maintenance of the hematocrit.
